Navigation Links
Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)

Will Begin Promotion in October At U.S. Psychiatric Congress

PARSIPPANY, N.J., Sept. 11 /PRNewswire/ -- Validus Pharmaceuticals, Inc. announced today that it has acquired the unique Bipolar Disorder treatment, Equetro(R) (carbamazepine) extended release capsules, from Shire plc.

EQUETRO(R) is a treatment for the acute manic and mixed episodes associated with Bipolar-1 Disorder -- a condition where patients experience extended periods of exaggerated highs in addition to the extended lows commonly associated with Bipolar Disorder. Equetro's patented advanced drug delivery technology also provides patients with the convenience of twice-daily dosing.

"This is a watershed moment in the commercialization of Validus Pharmaceuticals" stated James Hunter, Validus President & CEO. "Equetro(R) provides mental health professionals with an important treatment option in the management of Bipolar Disorder. Equetro(R) also fits well within our growing product portfolio which includes Marplan(R) (isocarboxazid), the classic MAO- inhibitor for treatment-resistant depression."

Validus Pharmaceuticals will begin active promotion of Equetro(R) during the U.S. Psychiatric & Mental Health Congress -- one of the nation's largest gatherings of mental health professionals -- in Orlando, FL in early October.

About Validus Pharmaceuticals:

Validus Pharmaceuticals is a specialty pharmaceutical company founded in Parsippany, NJ in 2007 to serve the unmet needs of patients with central nervous system (CNS) diseases. The company pursues this mission with targeted and focused marketing efforts and active acquisition and in-licensing programs aimed at underutilized CNS products that have important future potential. Validus is a portfolio company of the Konanda Pharma Fund I, L.P. in New York City. Please log-on to for additional information.

About Marplan(R)

Please go to the Marplan(R) website for Full Prescribing Information, including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO-inhibitors are contraindicated with certain drugs, and potential hypertensive crises may occur with tyramine containing foods. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially within the first few months of therapy.

About Equetro(R)

Please see complete Prescribing Information for Equetro at EQUETRO(R) contains carbamazepine. If you are currently taking another medication that contains carbamazepine, do not begin taking Equetro(R) without discussing this with your healthcare provider. Products that contain carbamazepine have been associated with rare but serious types of blood disorders. People with Bipolar Disorder have an increased risk for suicide. It is important to discuss risk factors for suicide with your healthcare provider.

About Konanda Pharma Fund I, L.P.

Konanda Pharma Fund I, L.P. is an investment fund that is managed by Konanda Pharma Partners, LLC, based in New York City. The Fund acquires mature branded drugs through portfolio companies which it owns and operates. Please log-on to for additional information.

SOURCE Validus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. WARF expands license agreement with Advanced Cell Technology
4. Verizon expands broadband service in Wisconsin
5. Bandwidth provider expands in Milwaukee
6. Wisconsins biodiesel network expands
7. Quad/Graphics expands reach in western states
8. University of South Florida expands GE Healthcare relationship
9. Metavante expands healthcare payments division
10. Fiserv expands services to health plan market
11. Bone Care expands patent protection of core drug offering
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, Hungary, ... be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has ... it now. , Biomarkers are components in the blood, tissue or body ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
Breaking Biology Technology:
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - ... ... ... With ...
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):